OTLK - Outlook Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
9/29/2018
9/29/2017
9/29/2016
Total Revenue
3,064
3,088
3,812
2,980
Cost of Revenue
-
-
-
-
Gross Profit
-
-
-
-
Operating Expenses
Research Development
26,461
18,504
23,810
33,102
Selling General and Administrative
12,624
14,228
15,882
21,636
Total Operating Expenses
39,085
32,732
39,692
54,738
Operating Income or Loss
-36,021
-29,644
-35,880
-51,758
Interest Expense
-
-
-
-
Total Other Income/Expenses Net
2,480
-205
3,158
0
Income Before Tax
-37,902
-33,740
-38,348
-53,226
Income Tax Expense
-1,275
-3,648
502
103
Income from Continuing Operations
-36,627
-30,092
-38,849
-53,329
Net Income
-36,627
-30,092
-38,849
-53,329
Net Income available to common shareholders
-38,431
-48,019
-40,026
-63,166
Reported EPS
Basic
-
-9.76
-13.36
-29.36
Diluted
-
-9.76
-14.40
-29.36
Weighted average shares outstanding
Basic
-
4,932
3,003
2,152
Diluted
-
4,932
3,005
2,152
EBITDA
-
-26,590
-33,188
-49,364